This overall loss of B cells was confirmed by immunophenotyping of the BM (Fig. 1F, Supplementary Fig. 1C) and is consistent with prior studies on low-risk (LR) MDS and SF3B1-mutated MDS48–51. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.